Medicine:WIBP-CorV
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Killed/Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
WIBP-CorV is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. The other inactivated virus COVID-19 vaccine developed by Sinopharm is BBIBP-CorV which is comparably more successful.
Development
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BBIBP-CorV)[1] and the Wuhan Institute of Biological Products (WIBP-CorV).[2] Both vaccines are chemically-inactivated whole virus vaccines for COVID-19.
On August 13, the Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[2]
Sinopharm said WIBP-CorV efficacy is 72.51%, lower than the 79.34% efficacy of BBIBP-CorV. On February 25, China approved WIBP-CorV for general use.[3][4] On March 10, Cayetano Heredia University running the BBIBP-CorV and WIBP-CorV trials in Peru announced they were seeking to suspend and unblind participants in the WIBP-CorV trials for lower efficacy and offer the participants BBIBP-CorV instead, which was showing efficacy.[5]
Authorization
According to New York Times, the WIBP-CorV is only approved for limited use in United Arab Emirates.[6]
References
- ↑ "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases 21 (1): 39–51. October 2020. doi:10.1016/s1473-3099(20)30831-8. PMID 33069281.
- ↑ 2.0 2.1 "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA 324 (10): 951–960. September 2020. doi:10.1001/jama.2020.15543. PMID 32789505.
- ↑ Eddy, Melissa (2021-02-25). "As Infections Dip, Governors Across U.S. Start Easing Restrictions" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/live/2021/02/25/world/covid-19-coronavirus.
- ↑ Staff, Reuters (2021-02-25). "China approves two more domestic COVID-19 vaccines for public use" (in en). Reuters. https://www.reuters.com/article/us-health-coronavirus-china-vaccine-idUSKBN2AP1MW.
- ↑ "COMUNICADO A LA OPINIÓN PÚBLICA". March 9, 2021. https://www.cayetano.edu.pe/cayetano/es/noticias/997-comunicado-a-la-opinion-publica-6.
- ↑ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee. "Coronavirus Vaccine Tracker" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html.
External links
 |
